Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Biomarker Study of Acamprosate in Schizophrenia
Biomarker Study of Acamprosate in Schizophrenia
Status: Enrolling
Updated:  12/21/2017
Keypoint Community Mental Health Centers- Dundalk
mi
from
Baltimore, MD
Biomarker Study of Acamprosate in Schizophrenia
Biomarker Study of Acamprosate in Schizophrenia
Status: Enrolling
Updated: 12/21/2017
Keypoint Community Mental Health Centers- Dundalk
mi
from
Baltimore, MD
Click here to add this to my saved trials
Biomarker Study of Acamprosate in Schizophrenia
Biomarker Study of Acamprosate in Schizophrenia
Status: Enrolling
Updated:  12/21/2017
VA Maryland Health Care System
mi
from
Baltimore, MD
Biomarker Study of Acamprosate in Schizophrenia
Biomarker Study of Acamprosate in Schizophrenia
Status: Enrolling
Updated: 12/21/2017
VA Maryland Health Care System
mi
from
Baltimore, MD
Click here to add this to my saved trials
Neurophysiological Targets for Cognitive Training in Schizophrenia
Neurophysiological Targets for Cognitive Training in Schizophrenia
Status: Enrolling
Updated:  12/21/2017
VA Connecticut Health Care System
mi
from
West Haven, CT
Neurophysiological Targets for Cognitive Training in Schizophrenia
Neurophysiological Targets for Cognitive Training in Schizophrenia
Status: Enrolling
Updated: 12/21/2017
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
Status: Enrolling
Updated:  1/9/2018
Massachusetts General Hospital
mi
from
Boston, MA
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
Status: Enrolling
Updated: 1/9/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
A Phase 1, Two-part, Open-label, Randomized, Exploratory and Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Brexpiprazole Long-acting Injectable Administered Subcutaneously or Intramuscularly in Adult Subjects With Schizophrenia
Status: Enrolling
Updated:  1/10/2018
Collaborative Neuro Science (CNS)
mi
from
Garden Grove, CA
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
A Phase 1, Two-part, Open-label, Randomized, Exploratory and Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Brexpiprazole Long-acting Injectable Administered Subcutaneously or Intramuscularly in Adult Subjects With Schizophrenia
Status: Enrolling
Updated: 1/10/2018
Collaborative Neuro Science (CNS)
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
A Phase 1, Two-part, Open-label, Randomized, Exploratory and Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Brexpiprazole Long-acting Injectable Administered Subcutaneously or Intramuscularly in Adult Subjects With Schizophrenia
Status: Enrolling
Updated:  1/10/2018
Cnri, Llc
mi
from
San Diego, CA
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
A Phase 1, Two-part, Open-label, Randomized, Exploratory and Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Brexpiprazole Long-acting Injectable Administered Subcutaneously or Intramuscularly in Adult Subjects With Schizophrenia
Status: Enrolling
Updated: 1/10/2018
Cnri, Llc
mi
from
San Diego, CA
Click here to add this to my saved trials
PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)
Improving PTSD Service Delivery for Veterans With Severe Mental Illness
Status: Enrolling
Updated:  1/11/2018
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)
Improving PTSD Service Delivery for Veterans With Severe Mental Illness
Status: Enrolling
Updated: 1/11/2018
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Click here to add this to my saved trials
Oxytocin and CBSST for People With Schizophrenia
Combined Oxytocin and CBSST for Social Function in People With Schizophrenia
Status: Enrolling
Updated:  1/11/2018
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Oxytocin and CBSST for People With Schizophrenia
Combined Oxytocin and CBSST for Social Function in People With Schizophrenia
Status: Enrolling
Updated: 1/11/2018
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oxytocin and CBSST for People With Schizophrenia
Combined Oxytocin and CBSST for Social Function in People With Schizophrenia
Status: Enrolling
Updated:  1/11/2018
University of California, San Diego
mi
from
San Diego, CA
Oxytocin and CBSST for People With Schizophrenia
Combined Oxytocin and CBSST for Social Function in People With Schizophrenia
Status: Enrolling
Updated: 1/11/2018
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Status: Enrolling
Updated:  1/12/2018
VA Connecticut Healthcare System
mi
from
West Haven, CT
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Status: Enrolling
Updated: 1/12/2018
VA Connecticut Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
Treatment of Refractory Schizophrenia With Riluzole
Neuroprotective Treatment of Refractory Schizophrenia With Riluzole 01T-432
Status: Enrolling
Updated:  1/12/2018
Yale Department of Psychiatry
mi
from
New Haven, CT
Treatment of Refractory Schizophrenia With Riluzole
Neuroprotective Treatment of Refractory Schizophrenia With Riluzole 01T-432
Status: Enrolling
Updated: 1/12/2018
Yale Department of Psychiatry
mi
from
New Haven, CT
Click here to add this to my saved trials
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia
Status: Enrolling
Updated:  1/16/2018
Baltimore VA Medical Center
mi
from
Baltimore, MD
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia
Status: Enrolling
Updated: 1/16/2018
Baltimore VA Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia
Status: Enrolling
Updated:  1/16/2018
Keypoint Health System
mi
from
Baltimore, MD
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia
Status: Enrolling
Updated: 1/16/2018
Keypoint Health System
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia
Status: Enrolling
Updated:  1/16/2018
Sheppard Pratt Health System
mi
from
Baltimore, MD
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia
Status: Enrolling
Updated: 1/16/2018
Sheppard Pratt Health System
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia
Status: Enrolling
Updated:  1/16/2018
Maryland Psychiatric Research Center (MPRC) Outpatient Research Program (ORP); the MPRC Treatment Research Program (TRP)
mi
from
Catonsville, MD
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia
Status: Enrolling
Updated: 1/16/2018
Maryland Psychiatric Research Center (MPRC) Outpatient Research Program (ORP); the MPRC Treatment Research Program (TRP)
mi
from
Catonsville, MD
Click here to add this to my saved trials
A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia
A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia
Status: Enrolling
Updated:  1/18/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia
A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia
Status: Enrolling
Updated: 1/18/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Naltrexone for Antipsychotic-Induced Weight Gain
Naltrexone for Antipsychotic-Induced Weight Gain
Status: Enrolling
Updated:  1/19/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Naltrexone for Antipsychotic-Induced Weight Gain
Naltrexone for Antipsychotic-Induced Weight Gain
Status: Enrolling
Updated: 1/19/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
Status: Enrolling
Updated:  1/22/2018
The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System
mi
from
Glen Oaks, NY
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
Status: Enrolling
Updated: 1/22/2018
The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System
mi
from
Glen Oaks, NY
Click here to add this to my saved trials
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated:  1/24/2018
VA Long Beach Healthcare System, Long Beach, CA
mi
from
Long Beach, CA
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated: 1/24/2018
VA Long Beach Healthcare System, Long Beach, CA
mi
from
Long Beach, CA
Click here to add this to my saved trials
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated:  1/24/2018
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated: 1/24/2018
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Click here to add this to my saved trials
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated:  1/24/2018
Overton Brooks VA Medical Center, Shreveport, LA
mi
from
Shreveport, LA
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated: 1/24/2018
Overton Brooks VA Medical Center, Shreveport, LA
mi
from
Shreveport, LA
Click here to add this to my saved trials
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated:  1/24/2018
VA Southern Nevada Healthcare System, North Las Vegas, NV
mi
from
Las Vegas, NV
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated: 1/24/2018
VA Southern Nevada Healthcare System, North Las Vegas, NV
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated:  1/24/2018
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated: 1/24/2018
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Click here to add this to my saved trials
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated:  1/24/2018
Northport VA Medical Center, Northport, NY
mi
from
Northport, NY
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated: 1/24/2018
Northport VA Medical Center, Northport, NY
mi
from
Northport, NY
Click here to add this to my saved trials
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated:  1/24/2018
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated: 1/24/2018
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Click here to add this to my saved trials
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated:  1/24/2018
Central Texas Veterans Health Care System, Temple, TX
mi
from
Temple, TX
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
Implementing Effective, Collaborative Care for Schizophrenia
Status: Enrolling
Updated: 1/24/2018
Central Texas Veterans Health Care System, Temple, TX
mi
from
Temple, TX
Click here to add this to my saved trials
Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation(SAPPHIRE Study)
Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation
Status: Enrolling
Updated:  1/30/2018
Durham VAMC
mi
from
Durham, NC
Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation(SAPPHIRE Study)
Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation
Status: Enrolling
Updated: 1/30/2018
Durham VAMC
mi
from
Durham, NC
Click here to add this to my saved trials
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Status: Enrolling
Updated:  2/2/2018
Massachusetts General Hospital
mi
from
Boston, MA
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Status: Enrolling
Updated: 2/2/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Improving Cognition in Schizophrenia Using tDCS
Improving Cognition in Schizophrenia Using Transcranial Direct Current Stimulation
Status: Enrolling
Updated:  2/6/2018
UCLA Semel Institute for Neuroscience and Human Behavior
mi
from
Los Angeles, CA
Improving Cognition in Schizophrenia Using tDCS
Improving Cognition in Schizophrenia Using Transcranial Direct Current Stimulation
Status: Enrolling
Updated: 2/6/2018
UCLA Semel Institute for Neuroscience and Human Behavior
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Imaging Cannabinoid CB1 Receptors in Schizophrenia
Imaging Cannabinoid CB1 Receptors in Schizophrenia
Status: Enrolling
Updated:  2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Imaging Cannabinoid CB1 Receptors in Schizophrenia
Imaging Cannabinoid CB1 Receptors in Schizophrenia
Status: Enrolling
Updated: 2/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
Clozapine Treatment of Schizophrenic Patients
Status: Enrolling
Updated:  2/14/2018
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
Clozapine Treatment of Schizophrenic Patients
Status: Enrolling
Updated: 2/14/2018
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Click here to add this to my saved trials
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D1 Dopamine, D2 Dopamine, and 5-HT6 Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700 in Male Patients With Schizophrenia
Status: Enrolling
Updated:  2/22/2018
US802
mi
from
Rockville, MD
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D1 Dopamine, D2 Dopamine, and 5-HT6 Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700 in Male Patients With Schizophrenia
Status: Enrolling
Updated: 2/22/2018
US802
mi
from
Rockville, MD
Click here to add this to my saved trials
Anti-Inflammatory Treatment of Schizophrenia
Anti-Inflammatory Combination Therapy for the Treatment of Schizophrenia
Status: Enrolling
Updated:  2/28/2018
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Anti-Inflammatory Treatment of Schizophrenia
Anti-Inflammatory Combination Therapy for the Treatment of Schizophrenia
Status: Enrolling
Updated: 2/28/2018
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Study Site
mi
from
Little Rock, AR
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Study Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Springdale, AR
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Springdale, AR
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Anaheim, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational site
mi
from
Culver City, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational site
mi
from
Culver City, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Garden Grove, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Irvine, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Irvine, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
La Jolla, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Long Beach, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
National City, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
National City, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Oakland, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Oakland, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Oceanside, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Orange, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
San Diego, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
San Francisco, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Torrance, CA
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Study Site
mi
from
Washington,
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Study Site
mi
from
Washington,
Click here to add this to my saved trials
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated:  2/28/2018
Alkermes Investigational Site
mi
from
Leesburg, FL
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Status: Enrolling
Updated: 2/28/2018
Alkermes Investigational Site
mi
from
Leesburg, FL
Click here to add this to my saved trials